NEW YORK (GenomeWeb) – Sygnis today reported a 64 percent increase in its first quarter revenues on strong sales of its research kits and devices.

For the three-month period ended March 31, the company's revenues rose to €2.3 million ($2.8 million) from €1.4 million in the same quarter the year before.

The Heidelberg, Germany-based firm posted a Q1 net loss of €322,000, or €.01 per share, down 73 percent from a loss of €1.2 million, or €.03 per share in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.

Sponsored by

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.